Advertisement

Journal of Molecular Medicine

, Volume 96, Issue 11, pp 1215–1225 | Cite as

Low-dose aspirin treatment enhances the adhesion of preeclamptic decidual mesenchymal stem/stromal cells and reduces their production of pro-inflammatory cytokines

  • Ramin Khanabdali
  • Aida Shakouri-Motlagh
  • Sarah Wilkinson
  • Padma Murthi
  • Harry M. Georgiou
  • Shaun P. Brennecke
  • Bill KalionisEmail author
Original Article

Abstract

Preeclampsia (PE) is a hypertensive disorder of human pregnancy. Low-dose aspirin (acetylsalicylic acid) (60–150 mg/day) is used to prevent PE when taken early in pregnancy. The effect of aspirin on term PE remains uncertain. Abnormal placentation is a hallmark of PE and leads to increased placental oxidative stress, which triggers the release of anti-angiogenic factors that cause local damage to the decidual vasculature. The damage subsequently spreads systemically and culminates in maternal clinical symptoms. Decidua basalis mesenchymal stem/stromal cells (DMSCs) reside in a vascular microenvironment. In PE, DMSCs are exposed to abnormally high levels of oxidative stress and circulating inflammatory factors from the maternal blood. We previously showed that colony-forming unit ability and resistance to oxidative stress in DMSCs are reduced in MSCs derived from term PE pregnancies (PE-DMSCs). The action, if any, of aspirin on term PE-DMSCs has not been reported. In this study, aspirin (5 μg/mL) was found to significantly increase PE-DMSC adhesion compared to untreated PE-DMSCs and gestation-matched control DMSCs (p value < 0.001) but had no effect on PE-DMSC proliferation. ELISA analysis showed that aspirin significantly decreased the production of inflammatory cytokines IFN-γ (p value < 0.05) and IL-8 (p value < 0.001) in PE-DMSCs. In addition, aspirin treatment increased the antioxidant capacity of PE-DMSCs compared with the untreated group (p value < 0.05). This study is the first to reveal a novel, beneficial action of aspirin on PE-DMSCs from term PE pregnancies by improving their adhesion, suppressing their production of pro-inflammatory cytokines production, and increasing their antioxidant capacity.

Key messages

  • Preeclampsia (PE) is a serious hypertensive disorder of pregnancy.

  • The risk of PE is reduced by aspirin but the mechanism is poorly understood.

  • Decidua basalis mesenchymal stem/stromal cells (DMSCs) are abnormal in PE.

  • Aspirin treatment improves multiple functions of PE-DMSCs.

  • Improved DMSC function may contribute to the beneficial effect of aspirin.

Keywords

Preeclampsia Aspirin Decidua Mesenchymal stem/stromal cells 

Notes

Acknowledgements

We acknowledge the patients who consented to provide their placenta, and the clinical research midwives at the Royal Women’s Hospital, Sue Duggan and Moira Stewart for sample collection.

Author contributions

Ramin Khanabdali: Conception and design, collection and assembly of data, data analysis and interpretations, manuscript writing, and final approval of the manuscript.

Aida Shakouri-Motlagh: Conception and design, collection and assembly of data, data analysis and interpretations, and final approval of the manuscript.

Sarah Wilkinson: Collection and assembly of data and final approval of the manuscript.

Padma Murthi: Manuscript editing and final approval of the manuscript.

Harry M Georgiou: Manuscript editing and final approval of the manuscript.

Shaun P. Brennecke: Provision of study material or patients and final approval of the manuscript.

Bill Kalionis: Conception and design, data interpretations, manuscript writing, and final approval of the manuscript.

Compliance with ethical standards

The study was approved by the Human Research Ethics Committee of the Royal Women’s Hospital, Victoria, Australia.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

109_2018_1695_MOESM1_ESM.docx (124 kb)
ESM 1 (DOCX 124 kb)

References

  1. 1.
    Ghulmiyyah L, Sibai B (2012) Maternal mortality from preeclampsia/eclampsia. Semin Perinatol 36(1):56–59CrossRefGoogle Scholar
  2. 2.
    Moodley J (2004) Maternal deaths associated with hypertensive disorders of pregnancy: population-based study. Hypertension Pregnancy 23(3):247–256CrossRefGoogle Scholar
  3. 3.
    Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Giguère Y (2010) Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 116(2, Part 1):402–414CrossRefGoogle Scholar
  4. 4.
    Roberge S, Nicolaides KH, Demers S, Villa P, Bujold E (2013) Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstetrics Gynecology 41(5):491–499CrossRefGoogle Scholar
  5. 5.
    Rolnik DL, Wright D, Poon LC, O’gorman N, Syngelaki A, de PacoMatallana C, Molina FS, Nicolaides KH (2017) Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 377(7):613–622CrossRefGoogle Scholar
  6. 6.
    Roberge S, Bujold E, Nicolaides KH (2018) Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol 218(3):287–293CrossRefGoogle Scholar
  7. 7.
    Cadavid AP (2017) Aspirin: the mechanism of action revisited in the context of pregnancy complications. Front Immunol 8:261CrossRefGoogle Scholar
  8. 8.
    Hui D, Okun N, Murphy K, Kingdom J, Uleryk E, Shah PS (2012) Combinations of maternal serum markers to predict preeclampsia, small for gestational age, and stillbirth: a systematic review. J Obstet Gynaecol Can 34(2):142–153CrossRefGoogle Scholar
  9. 9.
    Clifton VL, Stark MJ, Osei-Kumah A, Hodyl NA (2012) The feto-placental unit, pregnancy pathology and impact on long term maternal health. Placenta 33:S37–S41CrossRefGoogle Scholar
  10. 10.
    Thorp JA, Walsh SW, Brath PC (1988) Low-dose aspirin inhibits thromboxane, but not prostacyclin, production by human placental arteries. Am J Obstet Gynecol 159(6):1381–1384CrossRefGoogle Scholar
  11. 11.
    Chakraborty C, Gleeson LM, McKinnon T, Lala PK (2002) Regulation of human trophoblast migration and invasiveness. Can J Physiol Pharmacol 80(2):116–124CrossRefGoogle Scholar
  12. 12.
    Bose P, Black S, Kadyrov M, Weissenborn U, Neulen J, Regan L, Huppertz B (2005) Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol 192(1):23–30CrossRefGoogle Scholar
  13. 13.
    Han CS, Mulla MJ, Brosens JJ, Chamley LW, Paidas MJ, Lockwood CJ, Abrahams VM (2011) Aspirin and heparin effect on basal and antiphospholipid antibody modulation of trophoblast function. Obstet Gynecol 118(5):1021–1028CrossRefGoogle Scholar
  14. 14.
    Panagodage S, Yong HE, Costa FDS, Borg AJ, Kalionis B, Brennecke SP, Murthi P (2016) Low-dose acetylsalicylic acid treatment modulates the production of cytokines and improves trophoblast function in an in vitro model of early-onset preeclampsia. Am J Pathol 186(12):3217–3224CrossRefGoogle Scholar
  15. 15.
    Kusuma GD, Manuelpillai U, Abumaree MH, Pertile MD, Brennecke SP, Kalionis B (2015) Mesenchymal stem cells reside in a vascular niche in the decidua basalis and are absent in remodelled spiral arterioles. Placenta 36(3):312–321CrossRefGoogle Scholar
  16. 16.
    da Silva Meirelles L, Chagastelles PC, Nardi NB (2006) Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 119(11):2204–2213CrossRefGoogle Scholar
  17. 17.
    Kusuma GD, Abumaree MH, Pertile MD, Perkins AV, Brennecke SP, Kalionis B (2016) Mesenchymal stem/stromal cells derived from a reproductive tissue niche under oxidative stress have high aldehyde dehydrogenase activity. Stem Cell Rev Rep 12(3):285–297CrossRefGoogle Scholar
  18. 18.
    Hwang JH, Lee MJ, Seok OS, Paek YC, Cho GJ, Seol HJ, Oh MJ (2010) Cytokine expression in placenta-derived mesenchymal stem cells in patients with pre-eclampsia and normal pregnancies. Cytokine 49(1):95–101CrossRefGoogle Scholar
  19. 19.
    Rolfo A, Giuffrida D, Nuzzo AM, Pierobon D, Cardaropoli S, Piccoli E, Todros T (2013) Pro-inflammatory profile of preeclamptic placental mesenchymal stromal cells: new insights into the etiopathogenesis of preeclampsia. PLoS One 8(3):e59403CrossRefGoogle Scholar
  20. 20.
    Leonhardt A, Bernert S, Watzer B, Schmitz-Ziegler G, Seyberth HW (2003) Low-dose aspirin in pregnancy: maternal and neonatal aspirin concentrations and neonatal prostanoid formation. Pediatrics 111(1):77–81CrossRefGoogle Scholar
  21. 21.
    Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA (2007) Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 179(3):1855–1863CrossRefGoogle Scholar
  22. 22.
    Lyer SS, Rojas M (2008) Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Expert Opin Biol Ther 8(5):569–581CrossRefGoogle Scholar
  23. 23.
    Fu L, Liu Y, Zhang D, Xie J, Guan H, Shang T (2015) Beneficial effect of human umbilical cord derived mesenchymal stem cells on an endotoxin induced rat model of preeclampsia. Experimental Therapeutic Medicine 10(5):1851–1856CrossRefGoogle Scholar
  24. 24.
    Valle-Prieto A, Conget PA (2010) Human mesenchymal stem cells efficiently manage oxidative stress. Stem Cells Dev 19(12):1885–1893CrossRefGoogle Scholar
  25. 25.
    Chen JW, Zhou SB, Tan ZM (2010) Aspirin and pravastatin reduce lectin-like oxidized low density lipoprotein receptor-1 expression, adhesion molecules and oxidative stress in human coronary artery endothelial cells. Chin Med J 123(12):1553–1556PubMedGoogle Scholar
  26. 26.
    Wu Y, Zhai H, Wang Y, Li L, Wu J, Wang F et al (2012) Aspirin-triggered lipoxin A4 attenuates lipopolysaccharide-induced intracellular ROS in BV2 microglia cells by inhibiting the function of NADPH oxidase. Neurochem Res 37(8):1690–1696CrossRefGoogle Scholar
  27. 27.
    Zhang F, Lu M, Wang H, Ren T (2013) Aspirin attenuates angiotensin II induced inflammation in bone marrow mesenchymal stem cells via the inhibition of ERK1/2 and NF κB activation. Biomedical Reports 1(6):930–934CrossRefGoogle Scholar
  28. 28.
    Chamberlain G, Fox J, Ashton B, Middleton J (2007) Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 25(11):2739–2749CrossRefGoogle Scholar
  29. 29.
    Uccelli A, Moretta L, Pistoia V (2008) Mesenchymal stem cells in health and disease. Nature reviews. Immunology 8(9):726PubMedGoogle Scholar
  30. 30.
    Ehninger A, Trumpp A (2011) The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J Exp Med 208(3):421–428CrossRefGoogle Scholar
  31. 31.
    Tanimura S, Tadokoro Y, Inomata K, Binh NT, Nishie W, Yamazaki S et al (2011) Hair follicle stem cells provide a functional niche for melanocyte stem cells. Cell Stem Cell 8(2):177–187CrossRefGoogle Scholar
  32. 32.
    Alimperti S, Mirabella T, Bajaj V, Polacheck W, Pirone DM, Duffield J, Eyckmans J, Assoian RK, Chen CS (2017) Three-dimensional biomimetic vascular model reveals a RhoA, Rac1, and N-cadherin balance in mural cell–endothelial cell-regulated barrier function. Proc Natl Acad Sci 114(33):8758–8763CrossRefGoogle Scholar
  33. 33.
    Potapova IA, Gaudette GR, Brink PR, Robinson RB, Rosen MR, Cohen IS, Doronin SV (2007) Mesenchymal stem cells support migration, extracellular matrix invasion, proliferation, and survival of endothelial cells in vitro. Stem Cells 25(7):1761–1768CrossRefGoogle Scholar
  34. 34.
    Liu L, Zhao G, Fan H, Zhao X, Li P, Wang Z et al (2014) Mesenchymal stem cells ameliorate Th1-induced pre-eclampsia-like symptoms in mice via the suppression of TNF-α expression. PLoS One 9(2):e88036CrossRefGoogle Scholar
  35. 35.
    Tang J, Xiong J, Wu T, Tang Z, Ding G, Zhang C et al (2014) Aspirin treatment improved mesenchymal stem cell immunomodulatory properties via the 15d-PGJ2/PPARγ/TGF-β1 pathway. Stem Cells Dev 23(17):2093–2103CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Maternal-Fetal Medicine Pregnancy Research CentreThe Royal Women’s HospitalParkvilleAustralia
  2. 2.Department of Obstetrics and Gynaecology, Melbourne Medical SchoolThe University of MelbourneParkvilleAustralia
  3. 3.Department of Medicine, School of Clinical SciencesMonash UniversityClaytonAustralia
  4. 4.The Ritchie CentreHudson Institute of Medical ResearchClaytonAustralia

Personalised recommendations